This notion has been recently strengthened by a study that examined the effects of the genetic loss-of-function variants of Angptl3 and Angptl4, showing that genetic mimicry of ANGPTL4 inhibition is associated with an improved insulin-glucose metabolism and a lower risk of T2D and coronary artery disease [9]. The gene discussed is ANGPTL4; the disease is coronary artery disorder.